A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.

NCT Number	NCT06971523
Lead Sponsor	CytosinLab Therapeutics Co., Ltd.
Conditions	Solid Tumor, Lymphoma
Enrollment	224 participants
Start Date	2024-12-25
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-14